Literature DB >> 16133068

Lymphocyte adenosine deaminase activity in children with idiopathic nephrotic syndrome.

Om P Mishra1, Jayant Ghosh, Ziledar Ali, Malay Sen, Rajniti Prasad.   

Abstract

Adenosine deaminase (ADA) activity, as a marker of cell-mediated immunity, was evaluated in the serum (S-ADA) and lymphocytes (L-ADA) of 47 children with idiopathic nephrotic syndrome, and 23 healthy controls. The mean S-ADA and L-ADA levels were significantly raised in active nephrotic syndrome (ANS) and in its sub-groups in comparison with controls. The ADA activity was significantly more elevated in relapsers than for the first attack of nephrotic patients, and the frequent relapsers had the highest enzymatic levels both in serum as well as lymphocytes. A significant positive correlation was found between serum and lymphocyte ADA levels (r =0.736, p <0.01). In remission, the S-ADA showed a significant fall in comparison with their corresponding ANS value (p <0.001) and reached the level of controls. The mean L-ADA also showed reduction but the difference was statistically insignificant and the value was significantly raised, when compared with controls. The enzyme activity in serum and lymphocytes normalized in the long-term remission group. Thus, ADA activity was abnormal in ANS cases, and L-ADA demonstrated change both in active as well as remission stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133068     DOI: 10.1007/s00467-005-1872-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  Adenosine deaminase activity in lymphoid cells during antibody production.

Authors:  J G HALL
Journal:  Aust J Exp Biol Med Sci       Date:  1963-02

2.  Mortality in second and third degree malnutrition.

Authors:  Federico Gomez; Rafael Ramos Galvan; Silvestre Frenk; Joaqiun Cravioto Munoz; Raquel Chavez; Judith Vazquez
Journal:  J Trop Pediatr (Lond)       Date:  1956-09

3.  Adenosine deaminase activity in lymphocytes.

Authors:  J L Sullivan; W R Osborne; R J Wedgewood
Journal:  Br J Haematol       Date:  1977-09       Impact factor: 6.998

4.  Serum and pleural adenosine deaminase. Correlation with lymphocytic populations.

Authors:  M F Baganha; A Pêgo; M A Lima; E V Gaspar; A R Cordeiro
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

5.  Lymphocytotoxins in primary renal disease.

Authors:  B S Ooi; A R Orlina; L Masaitis
Journal:  Lancet       Date:  1974-12-07       Impact factor: 79.321

6.  Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis.

Authors:  M A Piras; C Gakis; M Budroni; G Andreoni
Journal:  Br Med J       Date:  1978 Dec 23-30

7.  Adenosine deaminase activity in nephrotic syndrome.

Authors:  O P Mishra; R Garg; Z Ali
Journal:  J Trop Pediatr       Date:  1997-02       Impact factor: 1.165

8.  Clinical efficacy of levamisole in the treatment of primary nephrosis in children.

Authors:  J G Mongeau; P O Robitaille; F Roy
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

9.  Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome.

Authors:  S A Hulton; V Shah; M R Byrne; G Morgan; T M Barratt; M J Dillon
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

10.  Immunoregulatory treatment for minimal change nephrotic syndrome.

Authors:  K P Mehta; U Ali; M Kutty; U Kolhatkar
Journal:  Arch Dis Child       Date:  1986-02       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.